TNFRSF9 and neoplasm: Indeed, dabrafenib plus trametinib combination therapy together with anti-PD1 Abs increased the population of CD8+ T cells among TILs, enhancing the anti-tumor activity that was further improved by anti-4-1BB Abs [35].